Left Impella®-device as bridge from cardiogenic shock with acute, severe mitral regurgitation to MitraClip®-procedure: a new option for critically ill patients.


Journal

European heart journal. Acute cardiovascular care
ISSN: 2048-8734
Titre abrégé: Eur Heart J Acute Cardiovasc Care
Pays: England
ID NLM: 101591369

Informations de publication

Date de publication:
25 May 2021
Historique:
received: 03 08 2020
revised: 30 09 2020
accepted: 04 11 2020
pubmed: 24 2 2021
medline: 25 11 2021
entrez: 23 2 2021
Statut: ppublish

Résumé

Patients presenting with cardiogenic shock (CS) related to acute, severe mitral regurgitation (MR) are often considered too ill for immediate surgical intervention. Therefore, other less invasive techniques for haemodynamic stabilization should be explored. The purpose of this exploratory study was to investigate the feasibility and outcomes in patients with CS due to severe MR by using a novel approach combining haemodynamic stabilization with left Impella-support plus MR-reduction using MitraClip®. We analysed whether a combined left Impella®/MitraClip®-procedure in a rare population of CS-patients with acute MR requiring mechanical ventilation is a feasible strategy to recovery in patients who had been declined cardiac surgery. Six INTERMACS-1 CS-patients with acute MR were studied at two tertiary cardiac intensive care units. The mean EURO-II score was 39 ± 19% and age 66.8 ± 4.9 years. All patients had an initial pulmonary capillary wedge pressure >20 mmHg and pulmonary oedema necessitating invasive ventilation. Cardiac output was severely impaired (left ventricular outflow tract velocity time index 9.8 ± 1.8 cm), requiring mechanical circulatory support (MCS) (Impella®-CP; mean flow 2.9 ± 1.8 L per minute; mean support 9.7 ± 6.0 days). Despite MCS-guided unloading, weaning from ventilation failed due to persisting pulmonary oedema necessitating MR-reduction. In all cases, the severe MR was reduced to mild using percutaneous MitraClip®-procedure, followed by successful weaning from invasive ventilation. Survival to discharge was 86%, with all surviving and rare readmission for heart failure at 6 months. A combined Impella®/MitraClip®-strategy appears a novel, feasible alternative for weaning CS-patients presenting with acute, severe MR. Upfront Impella®-stabilization facilitates safe bridging to Mitraclip®-procedure and the staged approach facilitates successful weaning from ventilatory support.

Identifiants

pubmed: 33620436
pii: 6016151
doi: 10.1093/ehjacc/zuaa031
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

415-421

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.

Auteurs

Christophe Vandenbriele (C)

Department of Cardiovascular diseases, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium.
Department of Adult Intensive Care, Royal Brompton and Harefield NHS Foundation Trust, Sydney St, Chelsea, London SW3 6NP, UK.

Tim Balthazar (T)

Department of Cardiovascular diseases, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium.

James Wilson (J)

Department of Adult Intensive Care, Royal Brompton and Harefield NHS Foundation Trust, Sydney St, Chelsea, London SW3 6NP, UK.

Tom Adriaenssens (T)

Department of Cardiovascular diseases, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium.

Simon Davies (S)

Department of Cardiology, Royal Brompton and Harefield NHS Foundation Trust, London, UK.

Walter Droogne (W)

Department of Cardiovascular diseases, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium.

Christophe Dubois (C)

Department of Cardiovascular diseases, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium.

Ana Francisca Caetano (AF)

Department of Adult Intensive Care, Royal Brompton and Harefield NHS Foundation Trust, Sydney St, Chelsea, London SW3 6NP, UK.

Kaatje Goetschalckx (K)

Department of Cardiovascular diseases, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium.

Steven Jacobs (S)

Department of Cardiac surgery, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium.

Stefan Janssens (S)

Department of Cardiovascular diseases, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium.

Stephane Ledot (S)

Department of Adult Intensive Care, Royal Brompton and Harefield NHS Foundation Trust, Sydney St, Chelsea, London SW3 6NP, UK.

Bart Meyns (B)

Department of Cardiac surgery, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium.

Hatem Soliman-Aboumarie (H)

Department of Adult Intensive Care, Royal Brompton and Harefield NHS Foundation Trust, Sydney St, Chelsea, London SW3 6NP, UK.

Peter Verbrugghe (P)

Department of Cardiac surgery, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium.

Susanna Price (S)

Department of Adult Intensive Care, Royal Brompton and Harefield NHS Foundation Trust, Sydney St, Chelsea, London SW3 6NP, UK.
Department of Cardiology, Royal Brompton and Harefield NHS Foundation Trust, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH